Valneva Shareholders Back All AGM Resolutions as Board Elects New Chair
I'm LongbridgeAI, I can summarize articles.Valneva shareholders approved all AGM resolutions, including financial statements and office transfer to Lyon. The Board elected Dr. Gerd Zettlmeissl as new Chair. Analyst ratings are mixed: TipRanks rates it a Buy with an $18 target, while Spark AI assigns a Neutral rating due to weak financials and bearish technicals.
The latest announcement is out from Valneva ( (VALN) ).
Valneva SE, a France-based specialty vaccine maker listed on Nasdaq and Euronext Paris, focuses on targeted prophylactic vaccines for infectious diseases, using its commercial travel-vaccine portfolio to support late-stage candidates such as the only Lyme disease vaccine in advanced development and the world’s most clinically advanced Shigella program.
At its Annual General Meeting held on June 25, 2026 in Lyon, shareholders approved all Board-backed resolutions, including the 2025 financial statements, renewed capital authorizations and the formal transfer of the registered office to Lyon after the closure of the Nantes site. The AGM also reappointed five directors for staggered terms, and, in a subsequent Board meeting, named independent director and veteran vaccine executive Dr. Gerd Zettlmeissl as Chair, reinforcing governance continuity and strategic oversight as Valneva consolidates operations and pursues long-term value creation for investors.
The most recent analyst rating on (VALN) stock is a Buy
with a $18.00 price target.
To see the full list of analyst forecasts on Valneva stock,
see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
The score is held down primarily by weak financial performance (large losses, persistent cash burn, and rising leverage) and bearish technical trend signals. Earnings-call commentary adds near-term pressure from a guidance cut and margin/COGS issues, partially offset by pipeline/regulatory upside (Lyme) and planned cost reductions; valuation provides limited support due to negative earnings.
To see Spark’s full report on VALN stock,
click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The group leverages multiple vaccine modalities to deliver first-, best- or only-in-class products and currently sells three proprietary travel vaccines, while advancing a pipeline that includes a Lyme disease vaccine partnered with Pfizer and a leading Shigella candidate.
Average Trading Volume: 67,117
Technical Sentiment Signal: Sell
Current Market Cap: $497.1M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.